Indeed, strategies aiming at inactivating or eliminating CAFs have demonstrated vessel decompression and increased tumor vascularity [91, 92], aligning with similar findings observed in other contexts like vascular injury, where inhibiting TGFβ-mediated myofibroblast activation reduced vessel constriction [93] (Discussed in more detail in Sect. 7). The gene discussed is TGFB1; the disease is neoplasm.